Latest Regulatory News

Algorae Pharmaceuticals has advanced its AI drug discovery capabilities with the launch of AlgoraeOS v2 and secured key commercial partnerships, including a $3 million debt facility to support expansion in Australia and New Zealand.

Syrah Resources delivered a record quarter with a 34% rise in natural graphite production and advancing anode material qualification at its Vidalia facility, while navigating evolving US trade policies that could reshape its market dynamics.

GBM Resources has reported a successful Stage 1 drilling campaign at its Twin Hills gold project in Queensland, revealing significant high-grade gold mineralisation beyond existing resources. The company also advanced its portfolio strategy by divesting non-core assets and securing a substantial capital raise.

Top End Energy has strategically expanded into the US AI data center sector, positioning itself as a key land and energy partner to meet surging power demands.

DeSoto Resources has advanced its exploration in Guinea’s Siguiri Basin with a new JV alongside Fortuna Mining and impressive high-grade gold intercepts, supported by a recent $14 million capital raise.

Equus Energy has launched on the ASX with full ownership of the Equus Gas Project, backed by a $46 million conditional funding and gas sales agreement with Alcoa. The project aims to supply a significant new gas source for Western Australia’s LNG and domestic markets.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

American Tungsten & Antimony Ltd has acquired the Dutch Mountain Tungsten Project and its fully permitted processing facility in Utah, positioning itself to accelerate tungsten production in the US by bypassing lengthy federal permitting.

Stockland announces a 9-cent unfranked dividend for the half-year ending December 2025, alongside a Dividend Reinvestment Plan priced at $5.47 per security. The DRP offers investors a 1% discount and new securities issued will rank equally from the issue date.

LTR Pharma has marked a key milestone with over 1,000 SPONTAN prescriptions under Australia’s Special Access Scheme and is advancing clinical trials and US market preparations for its erectile dysfunction treatments.

Control Bionics has raised $3.8 million to fuel growth, forged a key distribution deal with Tobii, and integrated with Apple’s BCI protocol, while advancing its NeuroStrip and NeuroBounce platforms.

Rapid Critical Metals has launched a comprehensive scoping study for its NSW silver projects, backed by promising drilling results and advanced ore-sorting technology.